TRIM26: A Protein Involved in Cell Signaling, Inflammation, Cell Death and Stem Cell Proliferation

Target Name: TRIM26

NCBI ID: G7726

TRIM26

TRIM26: A Protein Involved in Cell Signaling, Inflammation, Cell Death and Stem Cell Proliferation

TRIM26 (TRIM26 variant 2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues.

Recent studies have identified TRIM26 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because TRIM26 plays a role in the regulation of cell signaling pathways that are often disrupted in these conditions, and in the development of neurotoxicity.

One of the key functions of TRIM26 is its role in the regulation of the microtubule network. Microtubules are a type of protein structure that helps keep cells organized and move in a coordinated manner. TRIM26 is involved in the formation and stability of microtubules, and is thought to play a key role in the regulation of cell division and growth.

In addition to its role in cell signaling, TRIM26 is also involved in the regulation of inflammation. Many diseases, including cancer, are characterized by chronic inflammation that is difficult to control. TRIM26 is thought to be involved in the regulation of the immune response and the production of pro-inflammatory cytokines, which are important drivers of inflammation.

Another function of TRIM26 is its role in the regulation of cell death. Cell death, also known as apoptosis, is an important mechanism for the regulation of tissue homeostasis and is involved in the development of diseases such as neurodegenerative diseases. TRIM26 is thought to be involved in the regulation of cell death, and is a potential drug target for diseases that are characterized by chronic cell death.

TRIM26 is also involved in the regulation of stem cell proliferation and differentiation. Stem cells are a type of cell that have the ability to develop into any type of cell in the body, and are a key driver of tissue repair and regeneration. TRIM26 is thought to be involved in the regulation of stem cell proliferation and differentiation, and is a potential drug target for diseases that are characterized by stem cell dysfunction or cancer.

In conclusion, TRIM26 is a protein that is involved in a variety of important functions in the body, including cell signaling, inflammation, cell death, and stem cell proliferation and differentiation. As a result, TRIM26 is a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of TRIM26 in these conditions, and to develop effective therapies that target this protein.

Protein Name: Tripartite Motif Containing 26

Functions: E3 ubiquitin-protein ligase which regulates the IFN-beta production and antiviral response downstream of various DNA-encoded pattern-recognition receptors (PRRs). Promotes nuclear IRF3 ubiquitination and proteasomal degradation. Bridges together TBK1 and NEMO during the innate response to viral infection leading to the activation of TBK1

The "TRIM26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets